Given the permanent and sustained MEK/ERK activation in HCC, one could speculate that the newly transformed hepatocyte should thus prime ERK2 functions while diminishing ERK1 prodeath activity. The gene discussed is MAPK3; the disease is hepatocellular carcinoma.